JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors

Kathryn A. F. Pennel, Phimmada Hatthakarnkul, Colin S. Wood, Guang-Yu Lian, Sara S. F. Al-Badran, Jean A. Quinn, Assya Legrini, Jitwadee Inthagard, Peter G. Alexander, Hester van Wyk, Ahmad Kurniawan, Umar Hashmi, Michael A. Gillespie, Megan Mills, Aula Ammar, Jennifer Hay, Ditte Andersen, Colin Nixon, Selma Rebus, David K. Chang, Caroline Kelly, Andrea Harkin, Janet Graham, David Church, Ian Tomlinson, Mark Saunders, Tim Iveson, Tamsin R. M. Lannagan, Rene Jackstadt, Noori Maka, Paul G. Horgan, Campbell S. D. Roxburgh, Owen J. Sansom, Donald C. McMillan, Colin W. Steele, Nigel B. Jamieson, James H. Park, Antonia K. Roseweir, Joanne Edwards
  1. Time:2024;
  2. Target:actin,CD3,CD45RO,CD68,CD8,FoxP3,Ki67,panCK,SMA,VEGF

Abstract

No content available at the moment!
Original document click

LitReview

No content available at the moment!